Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | RGS4 | P49798 | 1/20 | 0.43 |
| ▸ | RGS8 | P57771 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430703 | 0.86 | CNR1 (0.52) | RGS4RGS8ALDH1A1CNR1CNR2 | |
| SCHEMBL16474464 | 0.82 | DRD2 (0.44) | GSK3BSIGMAR1PTGS2ALDH1A1 | |
| SCHEMBL5449024 | 0.79 | SIGMAR1 (0.54) | SIGMAR1HRH3ALDH1A1KDM4E | |
| SCHEMBL5445065 | 0.79 | SDHB (0.54) | GSK3AGSK3BSIGMAR1HRH3MAOB | |
| SCHEMBL5439934 | 0.78 | SIGMAR1 (0.50) | SIGMAR1HRH3 | |
| SCHEMBL5437499 | 0.77 | PLA2G7 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL5437516 | 0.76 | TLR8 (0.49) | ALDH1A1CNR1CNR2KDM4E | |
| SCHEMBL5443008 | 0.75 | SDHB (0.49) | CNR1CNR2 | |
| SCHEMBL14410409 | 0.75 | CREBBP (0.46) | ALDH1A1KDM4E | |
| SCHEMBL5435873 | 0.75 | GRM2 (0.52) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | claimed |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8399493-B2 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | GSK3A 1471/4885GSK3B 1323/4885SIGMAR1 239/4885 |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRIA2 | GSK3A 1694/4885GSK3B 1493/4885SIGMAR1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.